BioNTech has signed an agreement with Novartis to expand fill-finish support for the company’s Covid-19 vaccine — made in collaboration with Pfizer in Slovenia.
The Ljubljana, Slovenia sterile manufacturing site will be used to fill at least 24 million doses in 2022, and under the terms of the agreement, Novartis will take bulk mRNA active ingredient from BioNTech, fill that into vials, and ship it back to them for distribution.
The agreement follows one signed earlier this year, when Novartis started filling for BioNTech at its Stein site in Switzerland in June after gaining approval from the EMA.
“Novartis continues to offer its world-class capabilities to other companies to take over manufacturing activities including a variety of technologies such as mRNA production and others,” the company said in a statement. “The specifics will be disclosed when we conclude specific agreements.”
Exacis links with CCRM for NK therapies
An immuno-oncology company based out of Cambridge, MA announced a partnership with the Toronto-based Centre for Commercialization of Regenerative Medicine Thursday to manufacture mRNA-engineered natural killer cell products.
Exacis Biotherapeutics will also receive a cash investment from CCRM Enterprises Holdings, the for-profit arm of CCRM.
“We welcome CCRM as a key partner to allow us to rapidly advance our virus-free manufacturing processes to make novel NK cell products that are engineered for performance and to avoid rejection. CCRM is a recognized leader in iPSC-derived cell therapy development and manufacturing and we are thrilled to have them as a partner,” Exacis CEO Gregory Fiore said in a statement.
Founded just last year, Exacis is focused on engineering off-the-shelf NK and T-cell therapies that target hematologic malignancies and solid tumors.
New South Wales to spend $95M on mRNA manufacturing
The government in New South Wales is looking to create a national hub for mRNA vaccine production.
Premier Dominic Perrottet said that the government will spend $95 million in a partnership with the new RNA Biosciences Alliance, which is made up of all the universities in NSW.
“We are the first state in Australia to deliver a pilot manufacturing facility to spearhead the establishment of a local RNA industry,” Perrottet said. “The COVID pandemic has demonstrated to the world that it is critically important that we have the capability to develop vaccines quickly and for our country to have sovereign capability.”
The facility will make a potential mRNA manufacturing industry possible domestically and gives the potential for the facility to scale up and down as needed for future pandemics.
Source : https://endpts.com/novartis-expands-manufacturing-with-pfizer-and-biontech-exacis-links-with-ccrm-for-nk-cell-therapies/758